Trial Profile

A Single-Arm, Multi-Centre, Open-Label Phase II Study of HA121-28 in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HA121 28 (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Sponsors CSPC ZhongQi Pharmaceutical Technology

Most Recent Events

02 Aug 2022 Status changed from not yet recruiting to recruiting.
07 Feb 2022 Planned End Date changed from 1 Nov 2023 to 1 Oct 2023.
07 Feb 2022 Planned primary completion date changed from 1 Mar 2023 to 1 Oct 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com